Evidence base: Human papillomavirus

A summary of the evidence behind the primary care management of human papillomavirus.

Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)
Colposcopy showing a lesion on the cervix caused by HPV (Photograph: SPL)

Clinical trials

  • Kelly RS, Patnick J, Kitchener HC et al on behalf of the NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011: 1-6. doi:10.1038/bjc.2011.326.

Cervarix: phase III trials

  • Lehtinen M, Paavonen J, Wheeler CM et al. For the HPV PATRICIA Study Group. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 89-99.
  • Wheeler CM, Castellsague X, Garland SM et al. For the HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011; 13(1): 100-10.

Gardasil: phase III trials

  • FUTURE II Study Group. Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 340: c3493.
  • Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2: 868-78.

 

[xhead] Curriculum

This topic falls under section 10.1 of the GP curriculum, Women’s Health.

 

[xhead] Online

 

Individual responses to patient questions from an expert panel

 

Provides information for doctors and patients in many European languages

 

  • Dr Szarewski has received conference sponsorship, honoraria and consultancy fees from GSK and Merck, Sharp and Dohme. She is an investigator in two GSK phase III HPV 16/18 vaccine trials
  • Women's Health conference, 27 September 2012, London.

 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP training: Useful resources when preparing for the AKT

GP training: Useful resources when preparing for the AKT

Dr Branavan Anandasundaram highlights useful resources that GP trainees can use to...

GP training: How to succeed in the AKT

GP training: How to succeed in the AKT

Dr Branavan Anandasundaram passed the AKT earlier this year with a score of 89.5%....

Medico-legal: Advice on prescribing opioids

Medico-legal: Advice on prescribing opioids

The MDU's Dr Ellie Mein advises on how to avoid the medico-legal risks associated...

Map: How CQC ratings for general practice vary across England

Map: How CQC ratings for general practice vary across England

An overwhelming 95% of GP practices in England are rated either 'good' or 'outstanding'...

Rise in GP waiting times 'driving more patients to Google health advice'

Rise in GP waiting times 'driving more patients to Google health advice'

Longer waits for GP appointments may be pushing more patients to search for health...

GP locum rates continue to rise in most parts of the UK, poll reveals

GP locum rates continue to rise in most parts of the UK, poll reveals

Average hourly rates received by locums have risen across England over the past 12...